Singapore markets open in 6 hours 36 minutes
Straits Times Index
3,264.53 -35.51 (-1.08%) S&P 500
5,185.42 -2.28 (-0.04%) Dow
39,024.34 +140.08 (+0.36%) Nasdaq
16,297.03 -35.52 (-0.22%) Bitcoin USD
62,709.20 -448.59 (-0.71%) CMC Crypto 200
1,328.36 +33.69 (+2.60%)
Innate Pharma S.A. (IPHA)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 01:07PM EDT. Market open.
| Previous close | 2.6300 |
| Open | 2.5600 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 2.5600 - 2.5600 |
| 52-week range | 1.8100 - 3.5700 |
| Volume | |
| Avg. volume | 9,377 |
| Market cap | 206.956M |
| Beta (5Y monthly) | 0.67 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update
MARSEILLE, France, May 07, 2024--Innate Pharma announces conference call and webcast for Q1 business update
- Business Wire
Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
MARSEILLE, France, April 15, 2024--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that the first patient was dosed in the Phase 2 dose expansion part of the Sanofi-sponsored clinical trial of SAR443579 / IPH6101 (NCT05086315), evaluating SAR443579 as a monotherapy for the treatment of blood cancers with high unmet needs, including relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia and hig
- Business Wire
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024
MARSEILLE, France, April 15, 2024--Innate Pharma to hold its Annual General Meeting of shareholders on May 23, 2024
© 2024 Yahoo. All rights reserved.